<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001855</url>
  </required_header>
  <id_info>
    <org_study_id>1906687954</org_study_id>
    <nct_id>NCT04001855</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Bathing Additives in Atopic Dermatitis</brief_title>
  <official_title>Evaluating the Effect of Bathing Additives in Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed project will be an open-label, split-arm, randomized controlled pilot study. Up&#xD;
      to 60 patients diagnosed with atopic dermatitis (eczema) will be enrolled in the study. The&#xD;
      purpose of this study is to understand the change in skin barrier function and skin microbial&#xD;
      composition in patients with atopic dermatitis following dilute bleach bath/soak and dilute&#xD;
      vinegar bath/soak.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atopic dermatitis (AD), also known as eczema, is an inflammatory skin condition that affects&#xD;
      children and adults and causes skin redness, dryness and itching. Dilute bleach baths are&#xD;
      standard of care for treatment of AD and work to decrease skin inflammation and modulate the&#xD;
      skin microbiome. Dilute vinegar (acetic acid) has been reported to have similar effects on&#xD;
      the skin. The purpose of this study is to evaluate the change in skin barrier function and&#xD;
      skin microbial composition following baths or gauze soaks with dilute bleach and dilute&#xD;
      vinegar.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left university&#xD;
  </why_stopped>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control split body study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin barrier function - Transepidermal water loss (TEWL)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Assess skin barrier function through measurement of transepidermal water loss (in g/m^2h) using a commercially-available, non-invasive device (Delfin VapoMeter: http://www.delfintech.com/en/product_information/vapometer/).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin barrier function - Stratum corneum hydration</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Assess skin barrier function through measurement of stratum corneum hydration (in arbitrary units) using a commercially-available, non-invasive device (Delfin MoistureMeterSC: http://www.delfintech.com/en/product_information/moisturemetersc/).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin barrier function - pH</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Assess skin barrier function through measurement of stratum corneum pH (in pH units) using a commercially-available, non-invasive device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin culture swab</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Assess microbial composition via collection of non-invasive, non-painful skin culture swab samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Up to 21 days.</time_frame>
    <description>Clinical grading of atopic dermatitis/eczema severity (higher EASI scores indicating more severe AD).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Dilute vinegar vs. dilute bleach bath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilute vinegar vs. dilute bleach gauze soaks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dilute vinegar (acetic acid)</intervention_name>
    <description>Dilute vinegar baths or gauze soaks</description>
    <arm_group_label>Dilute vinegar vs. dilute bleach bath</arm_group_label>
    <arm_group_label>Dilute vinegar vs. dilute bleach gauze soaks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dilute bleach</intervention_name>
    <description>Dilute bleach baths or gauze soaks</description>
    <arm_group_label>Dilute vinegar vs. dilute bleach bath</arm_group_label>
    <arm_group_label>Dilute vinegar vs. dilute bleach gauze soaks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, at least 5 years of age&#xD;
&#xD;
          -  Subjects, parents/legal guardians must be able to comprehend and read the English&#xD;
             language&#xD;
&#xD;
          -  Subjects must have a diagnosis of atopic dermatitis (AD) by a board-certified&#xD;
             dermatologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who do not fit the inclusion criteria&#xD;
&#xD;
          -  Subjects unable or unwilling to comply with the study procedures&#xD;
&#xD;
          -  Concurrently have other inflammatory skin conditions&#xD;
&#xD;
          -  Prior known allergies to any components of the materials used&#xD;
&#xD;
          -  A subject who in the opinion of the investigator will be uncooperative or unable to&#xD;
             comply with study procedures&#xD;
&#xD;
          -  Subject unable to speak or read the English language&#xD;
&#xD;
          -  Those that are pregnant, prisoners or cognitively impaired&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner University Medicine Dermatology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetic Acid</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

